Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-NOTA-PTDGd is a radiolabeled peptide-based PET imaging agent developed for the non-invasive assessment of galectin-1 (Gal-1) expression, which serves as a surrogate marker for tumor hypoxia. The tracer consists of the PTDGd peptide, which exhibits high affinity for Gal-1, conjugated to the chelator NOTA and labeled with the positron-emitting isotope Gallium-68. Galectin-1 is a carbohydrate-binding protein that is significantly upregulated in the hypoxic regions of various solid tumors and plays a critical role in tumor angiogenesis, immunosuppression, and metastasis. By targeting Gal-1, 68Ga-NOTA-PTDGd allows for the visualization and quantification of hypoxic tumor microenvironments, potentially aiding in tumor staging, treatment planning, and monitoring response to therapies that target hypoxia or Gal-1. The development is primarily associated with researchers at Peking University.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 68Ga-NOTA-PTDGd.